

AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as follows:

On page 2, lines 12 and 22, please amend the paragraph as follows:

In recent years, pharmacological studies on 5-HT receptor subtypes have been conducted. For example, it has been reported that a 5-HT_{2B} receptor antagonist inhibits leakage of protein into outside of guinea pig mCPP induced dural blood vessel (*Cephalalgia* (2003) 23, 117 - 123), and that the 5HT_{2B} receptor localizing on vascular smooth muscle causes NO release, and the NO accelerates release of CGRP, substance P and the like nervous peptides from trigeminal nerve (*J. Biol. Chem.* (2000) 275, 9324 - 9331, *Circ. Res.* (1992) 70, 1313 - 1319). In addition, a result which suggests the effect to prevent migraine has been obtained by an animal model test using a compound (RS-127445) having selective binding affinity for the 5-HT_{2B} receptor (~~Cluster Headache and Related Conditions, vol. 9, edited by D. W. Bonhaus (England), Oxford University Press (1999), 278 - 286~~) (non-patent literature 1).

On page 6, lines 23-26, please amend the paragraph as follows:

Fig. 1 shows a graph which indicates the results of measurement of the amount of leaked proteins after administration of RS-127445 in a migraine model of guinea pig in the ~~test method (4)~~ example 1. Statistical testing was made by the Dunnett's test; * indicates probability value is less than 5%, and ** indicates that is less than 1%.

On page 7, lines 1-4, please amend the paragraph as follows:

Fig. 2 shows a graph which indicates the results of measurement of the amount of leaked proteins after administration of SB-269970 in a migraine model of guinea pig in the ~~test method (4)~~ example 1. Statistical testing was made by the Dunnett's test; ** indicates probability value is less than 1%.

On page 7, lines 5-8, please amend the paragraph as follows:

Fig. 3 shows a graph which indicates the results of measurement of the amount of leaked proteins after simultaneous administration of RS-127445 and SB-269970 in a migraine model of guinea pig in the ~~test method (4)~~ example 1. Statistical testing was made by the T test; * indicates probability value is less than 5%.

On page 7, lines 9-12, please amend the paragraph as follows:

Fig. 4 shows a graph which indicates the results of measurement of the amount of leaked proteins after administration of the compound of Example 3 in a migraine model of guinea pig in the ~~test method (4)~~ example 1. Statistical testing was made by the T test; * indicates probability value is less than 5%.

On page 10, line 25, to page 11, line 8, please amend the paragraph as follows:

The "5-HT₇ selective antagonistic compound" of the invention can be found by accomplishing a receptor affinity screening method as described in Reference Examples 2 and 3 below or a similar method thereto. The compounds, specifically, includes for example known 5-HT₇ selective antagonistic compounds, DR-4004 (J. Med.

Chem. (1999) 42, 533), SB-269970 (J. Med. Chem. (2000) 43, 342-345), SB-691673 (Bioorg. Med. Chem. Lett. (2003) 13, 1055-1058), aminotriazole derivatives (Bioorg. Med. Chem. Lett. (2004) 14, 4245-4248), aminotetralin derivatives (J. Med. Chem. (2004) 47, 3927-3930), aminochromane derivatives (J. Med. Chem. (2004) 47, 3927-3930), 11-phenylapomorphine derivatives (J. Med. Chem. (2001) 44, 1337-1340) and the like, as far as they are 5-HT₇ receptor selective compounds.

On page 16, lines 4-8, please amend the paragraph as follows:

DR-4004: J. Med. Chem. (1999) 42, 533; SB-269970: J. Med. Chem. (2000) 43, 342-345; SB-691673: Bioorg. Med. Chem. Lett. (2003) 13, 1055-1058; aminotriazole derivatives: Bioorg. Med. Chem. Lett. (2004) 14, 4245-4248; aminotetraline derivatives: J. Med. Chem. (2004) 47, 3927-3930; aminochromane derivatives: J. Med. Chem. (2004) 47, 3927-3930; 11-phenylapomorphine derivatives: J. Med. Chem. (2001) 44, 1337-1340.

On page 30, lines 7-12, please amend the paragraph as follows:

2-Fluoro-4'-methyl-6-nitrobiphenyl [FAB-MS: 232 (M + H)⁺] was obtained from 2-fluoro-6-nitrophenyl trifluoromethanesulfonate and 4-methylphenylboric acid by carrying out the reaction in the same manner as in Reference Preparation 1-a, and converted into (6-fluoro-4'-methylbiphenyl-2-yl)amine [EI-MS: 201 (M)⁺] by subjecting this nitro group to catalytic hydrogenation reduction, and then Sandmeyer reaction was carried out to obtain 2-bromo-6-fluoro-4'-methylbiphenyl. EI-MS: 266 (M)⁺, 268 [(M)⁺], (M+2)⁺.

On page 55, lines 9-19, please amend the paragraph as follows:

In this connection, affinities of each of RS-127445 (2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine; see WO 97/44326 for its production method) and SB-269970 ((R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol; see WO 97/48681 for its production method) described in the following example 1 for respective receptors are conventionally known, and regarding the RS-127445, it has been reported that said compound has a pKi value of 9.5 for 5-HT_{2B} receptor, and is 1000 times more 5-HT_{2B} receptor selective against 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₆, 5-HT₇, α_1 , M₁, D₂ receptors. Also, regarding the SB-269970, it has been reported, for example in *J. Med. Chem.* (2000) 43, 342 - 345, that said compound has a pKi value of 8.9 for [[5-HT_{2B}]] 5-HT₇ receptor, and is 250 times more 5-HT₇ receptor selective against 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C}, 5-HT₄, 5-HT₆, α_1 , and D₂ receptors.